News Related to Anti-CD38 Antibody

Related coverage linked through entity extraction aliases.

FDA Approves Two Johnson & Johnson Multiple Myeloma Regimens in Early 2026

Mar 06, 2026

The FDA approved Tecvayli plus Darzalex Faspro for relapsed/refractory multiple myeloma in March 2026, and Darzalex Faspro-based quadruplet D-VRd for newly diagnosed transplant-ineligible patients in January 2026.

C4 Therapeutics Doses First Patient in Phase 2 Myeloma Trial, Targets 2028 NDA Submission

Mar 08, 2026

C4 Therapeutics has initiated its Phase 2 MOMENTUM trial of cemsidomide in relapsed/refractory multiple myeloma, targeting enrollment completion in Q1 2027 and a registrational dataset by 2028. The company plans a combination study with elranatamab in Q2 2026.